PolyNovo Limited

ASX PNV.AX

PolyNovo Limited Price to Sales Ratio (P/S) on January 14, 2025: 13.15

PolyNovo Limited Price to Sales Ratio (P/S) is 13.15 on January 14, 2025, a -18.38% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

PolyNovo Limited 52-week high Price to Sales Ratio (P/S) is 26.23 on March 13, 2024, which is 99.53% above the current Price to Sales Ratio (P/S).
PolyNovo Limited 52-week low Price to Sales Ratio (P/S) is 12.34 on January 12, 2025, which is -6.17% below the current Price to Sales Ratio (P/S).
PolyNovo Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 18.09.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

ASX: PNV.AX

PolyNovo Limited

CEO	Mr. Swami Raote BPHARM, M.B.A.
IPO Date	Nov. 30, 1998
Location	Australia
Headquarters	320 Lorimer Street
Employees	254
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Key trends

Past 5 years